Activating the Caretakers

Astrocytes are considered the natural caretakers of the brain and are the most abundant cell type in the human brain 1,2.  Astrocytes provide metabolic and trophic support to neurons and they modulate synaptic activity 3.  After brain injury, astrocytes play pivotal roles in restoring ion balance, controling edema and removing toxic neurotransmitters 4-6.  These neuroprotective activites are highly energy-dependent and require astrocyte mitochondria 7,8.  Notably, neurons are permanently injured after ischemia only if astrocyte mitochondrial function fails 9,10.  Inhibition of astrocyte mitochondria increases cell swelling and induces cell death11. Excitotoxicity, due to high extracellular glutamate, is also principally controled by astrocytes and requires membrane polarization – the energy-dependent maintenance of the Na+ ion gradient12-14.

Astrocytes are ‘activated’ when the production of inositol (1,4,5) triphosphate (IP3) triggers intracellular Ca2+ release from thapsigargin-sensitive stores in the endoplasmic reticulum (ER), which can be initiated by multiple G-protein coupled receptors including our target receptor 15-18.  During astrocyte activation, mitochondria, in turn, sequester some of the released Ca2+ and utilize it to activate Ca2+ sensitive dehydrogenases in the tricarboxylic citric acid cycle (TCA).  This signaling cascade thereby increases oxidative phosphorylation and ultimately, significant production of ATP19-21.

Results from our laboratory in mouse models of stroke and blunt trauma TBI show that treatment with a novel purinergic agonist, significantly reduces early brain damage 17,18,22.  These agonists selectively enhance mitochondrial ATP production in astrocytes by stimulating IP3-mediated Ca2+ release, which, in turn, enhance their energy-dependent neuroprotective functions.  Pharmacological and genetic manipulation show that receptor activation not only increases neuronal and astrocyte survival but also partially reverses neuronal and glial damage.  Our data also show that the protective pathway activated by our purinergic agonists is conserved in ex vivo human brain tissue experiments (unpublished), emphasizing the potential for this novel approach to be an effective therapy for human brain injuries.

MOA Schematic

 

  1. Cherniak, C. The bounded brain: toward quantitative neuroanatomy. J Cogn Neurosci 2, 58-68 (1990).
  2. Nedergaard, M., Ransom, B. & Goldman, S.A. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci 26, 523-30 (2003).
  3. Chen, Y. & Swanson, R.A. Astrocytes and brain injury. J Cereb Blood Flow Metab 23, 137-49 (2003).
  4. Nedergaard, M. Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science 263, 1768-71 (1994).
  5. Parpura, V. et al. Glutamate-mediated astrocyte-neuron signalling. Nature 369, 744-7 (1994).
  6. Haydon, P.G. GLIA: listening and talking to the synapse. Nat Rev Neurosci 2, 185-93 (2001).
  7. Hertz, L., Peng, L. & Dienel, G.A. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J Cereb Blood Flow Metab 27, 219-49 (2007).
  8. Watts, L.T. & Lechleiter, J.D. The impact of astrocyte mitochondrial metabolism on neuroprotection during aging. in Astrocytes in (patho) physiology of the nervous system (eds. Parpura, V. & Haydon, P.G.) 569-590 (Springer, Boston, MA, 2008).
  9. Largo, C., Cuevas, P. & Herreras, O. Is glia disfunction the initial cause of neuronal death in ischemic penumbra? Neurol Res 18, 445-8 (1996).
  10. Largo, C., Cuevas, P., Somjen, G.G., Martin del Rio, R. & Herreras, O. The effect of depressing glial function in rat brain in situ on ion homeostasis, synaptic transmission, and neuron survival. J Neurosci 16, 1219-29 (1996).
  11. Chu, X. et al. Oncosis, the possible cell death pathway in astrocytes after focal cerebral ischemia. Brain Res 1149, 157-64 (2007).
  12. Sonnewald, U., Westergaard, N. & Schousboe, A. Glutamate transport and metabolism in astrocytes. Glia 21, 56-63 (1997).
  13. Chatton, J.Y., Marquet, P. & Magistretti, P.J. A quantitative analysis of L-glutamate-regulated Na+ dynamics in mouse cortical astrocytes: implications for cellular bioenergetics. Eur J Neurosci 12, 3843-53 (2000).
  14. Oliet, S.H., Piet, R. & Poulain, D.A. Control of glutamate clearance and synaptic efficacy by glial coverage of neurons. Science 292, 923-6 (2001).
  15. James, G. & Butt, A.M. P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system. Eur J Pharmacol 447, 247-60 (2002).
  16. Verkhratsky, A. & Kettenmann, H. Calcium signalling in glial cells. Trends Neurosci 19, 346-52 (1996).
  17. Zheng, W., Talley Watts, L., Holstein, D.M., Wewer, J. & Lechleiter, J.D. P2Y1R-initiated, IP3R-dependent stimulation of astrocyte mitochondrial metabolism reduces and partially reverses ischemic neuronal damage in mouse. J Cereb Blood Flow Metab 33, 600-11 (2013).
  18. Talley Watts, L. et al. Purinergic 2Y(1) receptor stimulation decreases cerebral edema and reactive gliosis in a traumatic brain injury model. J Neurotrauma 30, 55-66 (2013).
  19. Denton, R.M. & McCormack, J.G. Ca2+ transport by mammalian mitochondria and its role in hormone action. Am. J. Physiol 259, E543-E554 (1985).
  20. Hajnoczky, G., Csordas, G., Krishnamurthy, R. & Szalai, G. Mitochondrial calcium signaling driven by the IP3 receptor. J Bioenerg Biomembr 32, 15-25 (2000).
  21. McCormack, J.G. & Denton, R.M. Signal transduction by intramitochondrial Ca2+ in mammalian energy metabolism. NIPS 9, 71-76 (1994).
  22. Zheng, W. et al. Purinergic receptor stimulation reduces cytotoxic edema and brain infarcts in mouse induced by photothrombosis by energizing glial mitochondria. PLoS One 5, e14401 (2010).

Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders